Subscribe to Newsletter

Manufacture


Manufacture Advanced Medicine

Fear Replaced by Understanding, Optimism, and Miracles: Part II

| Daniel Eisenman | 7 min read

Accelerating the progress of cell and gene therapies with decentralized trials and other innovative approaches.

Manufacture Bioprocessing - Upstream & Downstream

Mastering Oligonucleotide Manufacturing

A selection of experts from Asahi Kasei Bioprocess discuss the key practices behind successful processes.

Manufacture Advanced Medicine

Advancing CRISPR: Caszyme Collaborates with Integra Therapeutics

| 4 min read

We find out why Cas12l incorporated into a gene-writing system could help advance the field of gene editing.

Manufacture Bioprocessing - Upstream & Downstream

Accelerating Cell Line Development

| Brett Verstak | 5 min read

The essential roles of optimized cell lines and vectors in accelerating bioprocessing.

Manufacture Advanced Medicine

Meet the California Institute Pushing Stem Cell and Gene Therapy Research: Part 1

| Stephanie Vine | 6 min read

Consider CIRM as a bank. We don’t conduct research ourselves: we fund it – and have become the largest dedicated funder of stem cell and gene therapy

Manufacture Advanced Medicine

Charting the Rise of Cell and Gene Therapies

We look back on a decade of breakthroughs in advanced medicine – explore our top articles on cell and gene therapy.

Manufacture Vaccines

From mRNA to Equity: How the Vaccine Field Has Changed

A curated collection of articles examining critical questions and advancements in vaccine science and policy.

Manufacture Advanced Medicine

Pharma Fiction

| Rob Coker | 2 min read

A look back at The Medicine Maker archive and the influence of science fiction in the industry and science.

Manufacture Advanced Medicine

FDA or EMA Novel Drug Approvals 2024: Anagrams Edition

| Rob Coker

So you know your small molecule from your AAV, but can you unscramble the names of these 2024 novel drug approvals?

Manufacture Technology and Equipment

Pairing Genomic Medicine with AI

| 3 min read

A partnership between WhiteLab Genomics and Debiopharm will seek to use AI to streamline the development of targeted cancer therapies.


Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register